Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 10/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | PDE9A | O76083 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140381 | 0.86 | ELANE (0.56) | L3MBTL1ELANEPTGDR2APPSNCA | |
| SCHEMBL20140277 | 0.86 | ELANE (0.46) | L3MBTL1ELANEPTGDR2APPSNCA | |
| SCHEMBL20140783 | 0.84 | L3MBTL1 (0.63) | L3MBTL1ELANEPTGDR2APPSNCA | |
| SCHEMBL20140445 | 0.82 | ELANE (0.41) | L3MBTL1ELANE | |
| SCHEMBL20140434 | 0.81 | L3MBTL1 (0.46) | L3MBTL1ELANEAPPSNCA | |
| SCHEMBL20140374 | 0.81 | L3MBTL1 (0.49) | L3MBTL1ELANEPTGDR2APPSNCA | |
| SCHEMBL9925005 | 0.80 | L3MBTL1 (0.49) | L3MBTL1ELANEPTGDR2 | |
| SCHEMBL20140478 | 0.80 | ELANE (0.35) | L3MBTL1ELANEPDE9A | |
| SCHEMBL9925305 | 0.79 | ELANE (0.50) | L3MBTL1ELANEPTGDR2KDM4D | |
| SCHEMBL10063592 | 0.79 | ELANE (0.47) | L3MBTL1ELANEPTGDR2KDM4DAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-110267658-B | Treatment of CNS disorders with sGC stimulators | 帝善多制药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3538096-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885ELANE 2411/4885PTGDR2 114/4885 |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | L3MBTL1 4352/4885ELANE 2818/4885PTGDR2 223/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885ELANE 2419/4885PTGDR2 116/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | L3MBTL1 4352/4885ELANE 2818/4885PTGDR2 223/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885ELANE 2419/4885PTGDR2 116/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | L3MBTL1 4352/4885ELANE 2818/4885PTGDR2 223/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885ELANE 2411/4885PTGDR2 114/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | L3MBTL1 4186/4885ELANE 3806/4885PTGDR2 625/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | L3MBTL1 4352/4885ELANE 2818/4885PTGDR2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.